research Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
Search
for
Sort by
Research
930-960 / 1000+ results
research HAIR LOSS ASSOCIATED WITH ESCITALOPRAM: DO SSRIs AFFECT MELATONIN AT THE HAIR FOLLICLE?
The antidepressant escitalopram likely caused hair loss in a patient.
research A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
research Platelet-rich plasma improves caspase-3 of skin graft treated with Tilapia Mozambique bio-dressing
PRP with TM bio-dressing improves skin graft healing in cats.
research 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
research Response to: “Minimum requirements for reporting clinical trials evaluating the therapeutic potential of platelet-rich plasma”
The authors agree that standardizing how PRP methods are reported could help compare results, but note that the link between PRP's contents and hair growth is unclear, and recommend avoiding split-scalp designs in future trials.
research The Sodium Valproate: Doctor Jekyll and Mister Hyde
Sodium valproate is effective in treating epilepsy, especially in patients who don't respond to other medications.
research Daclizumab
Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
research A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism
Spironolactone plus finasteride reduces hirsutism more effectively.
research The Danish Health and Medicines Authority has issued a warning that split and crushed finasteride tablets may pose a risk to pregnant and fertile women.
Crushed finasteride tablets can harm pregnant and fertile women.
research Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
research Platelet Rich Plasma in Androgenic Alopecia: Where do we Stand?
Platelet Rich Plasma (PRP) shows promise for hair growth, ulcer healing, and skin rejuvenation, but more research is needed for consistent results and it's not suitable for people with certain blood conditions.
research 490 Samcyprone (diphenylcyclopropenone ointment) for the treatment of common warts
Samcyprone ointment is effective for treating common warts if a sensitization reaction occurs first.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Determination of finasteride in human plasma and its pharmacokinetics and relative bioavailability by HPLC-electrospray mass spectrometry
Two finasteride tablet formulations are bioequivalent.
research Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials
Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
research Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Finasteride Enhances the Generation of Human Myeloid-Derived Suppressor Cells by Up-Regulating the COX2/PGE2 Pathway
Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.
research Combined drug triads for synergic neuroprotection in retinal degeneration
Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
research PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
research NEW FORMULATIONS: Sodium cromoglycate
Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
research Valproic acid – induced Pleuro-pericardial Effusion
Valproic acid can rarely cause fluid buildup around the lungs and heart.
research Traumatic scalp arteriovenous fistula post capillary implantation successfully treated using PHIL embolic agent
A scalp blood vessel issue from hair transplant was successfully treated with a special liquid agent.
research Implementation and Evaluation of a Platelet-Rich Plasma Multimedia Patient Education Tool for Patients With Androgenetic Alopecia
The multimedia tool improved patient understanding of PRP treatment for hair loss.
research Hair Loss Induced by Lopinavir-Ritonavir
The medication lopinavir-ritonavir may cause severe hair loss.
research Response to “Improvement of female pattern hair loss with bicalutamide: a time-dependent process”
Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
research Overview and Future of Hemo-Components and Natural Guided Regeneration
The document concludes that more standardized research is needed to fully understand and optimize the use of platelet-rich fibrin in regenerative medicine.
research Oral bicalutamide for female pattern hair loss: A pilot study
Bicalutamide improves hair density in women safely.
research Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database
Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.